Medicare drug prices pegged to global benchmarks—but only for some
H.R. 7837 — Most Favored Patient Act of 2026 · Filed by Daniel Meuser (R-PA) · Introduced Mar 5, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires Medicare and Medicaid to test a 'Most Favored Nation' drug pricing model starting January 1, 2029, where pharmaceutical manufacturers must offer U.S. patients the second-lowest price that the drug sells for in eight wealthy countries (Canada, Denmark, France, Germany, Italy, Japan, Switzerland, UK). Manufacturers can avoid this requirement by signing a separate agreement with the government committing to increase U.S. manufacturing operations. The test runs for 5 years and applies to drugs covered by Medicare Part B, Part D, and Medicaid.
Why we flagged it
The bill's core mechanism is a regulatory price-control model that ties U.S. Medicare/Medicaid reimbursement to the second-lowest price in eight OECD countries. This is a direct intervention in pharmaceutical pricing, not a market-based or voluntary mechanism.
What the text implies
- The 'covered agreement' escape clause (allowing manufacturers to opt out if they commit to U.S. manufacturing) creates a de facto industrial policy incentive—manufacturers may relocate production to avoid price controls, shifting supply-chain risk and potentially raising costs elsewhere.
- The model applies only to drugs sold in at least 2 of 8 reference countries, potentially excluding rare or newly approved drugs, creating a two-tier system where some patients have price protections and others do not.
The full analysis lists 5 implications of this text.
Who stands to gain
Medicare beneficiaries (seniors); Medicaid beneficiaries (low-income individuals); Pharmacy benefit managers (if they capture savings)